- Home
- GAME vs ZURA Comparison
GAME vs ZURA Comparison
Compare GAME & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- ZURA
- Stock Information
- Founded
- GAME 2011
- ZURA 2022
- Country
- GAME United States
- ZURA United States
- Employees
- GAME N/A
- ZURA N/A
- Industry
- GAME
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GAME
- ZURA Health Care
- Exchange
- GAME Nasdaq
- ZURA Nasdaq
- Market Cap
- GAME 70.2M
- ZURA 69.9M
- IPO Year
- GAME 2009
- ZURA N/A
- Fundamental
- Price
- GAME $0.74
- ZURA $1.90
- Analyst Decision
- GAME Strong Buy
- ZURA Buy
- Analyst Count
- GAME 2
- ZURA 10
- Target Price
- GAME $3.00
- ZURA $12.67
- AVG Volume (30 Days)
- GAME 2.6M
- ZURA 292.6K
- Earning Date
- GAME 11-13-2025
- ZURA 11-06-2025
- Dividend Yield
- GAME N/A
- ZURA N/A
- EPS Growth
- GAME N/A
- ZURA N/A
- EPS
- GAME N/A
- ZURA N/A
- Revenue
- GAME $93,375,339.00
- ZURA N/A
- Revenue This Year
- GAME $2.32
- ZURA N/A
- Revenue Next Year
- GAME $26.42
- ZURA N/A
- P/E Ratio
- GAME N/A
- ZURA N/A
- Revenue Growth
- GAME 54.19
- ZURA N/A
- 52 Week Low
- GAME $0.50
- ZURA $0.97
- 52 Week High
- GAME $2.87
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- GAME 43.40
- ZURA 48.83
- Support Level
- GAME $0.70
- ZURA $1.88
- Resistance Level
- GAME $0.76
- ZURA $2.19
- Average True Range (ATR)
- GAME 0.05
- ZURA 0.14
- MACD
- GAME 0.01
- ZURA -0.04
- Stochastic Oscillator
- GAME 49.52
- ZURA 5.00
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.